Solving the Capacity Crisis for Viral Vector Manufacturing

Solving the Capacity Crisis for Viral Vector Manufacturing

Viral vectors for gene therapy have shown tremendous clinical promise which has spurred a huge increase in demand for manufacturing space, resulting in a capacity crisis. This is currently delaying the commercialization of these gene therapies for which time to market is critical.

Integrated solutions for viral vectors designed within modular cleanroom facilities streamline manufacturing and reduce time to market. Pall Biotech and G-CON manufacturing have partnered to design and deploy an integrated manufacturing solution to address the current capacity constraints for viral vector manufacturing.

Participants will learn:

  1. The manufacturing challenges facing the viral vector industry
  2. The advantages of an integrated manufacturing solution
  3. How to develop and deploy a new manufacturing facility in 10 months within a modular cleanroom

 

 

 

Moderator

 

 

Charlotte Masy

Clive Glover

 

Director, Cell & Gene Therapy
Pall Biotech

 

 

 

Presenters

 

 

 

Charlotte Masy

Jeremy Rautenbach

 

Global Product Manager, Integrated Solutions
Pall Biotech

Charlotte Masy

Joseph Rininger

 

Director, Cell & Gene Therapy
Latham BioPharm Group

Charlotte Masy

Peter Makowensky

 

Director, Sales Engineering

G-CON Manufacturing

Maximize Speed to Market Flexibility of Single-Use for Gene Therapy Manufacturing

Listen to Podcast Today

More Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
October 2020

From September 22nd to November 19th

 

There is no single vaccine manufacturing approach. There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale.

 

Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.

 

Diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist.

 

There are flexible technologies that can meet each of the challenges during PD and at GMP scale.

 

Join this webinar series and learn more about securing process quality with flexible manufacturing solutions.

 

Webinars available

 

  • Vaccines development, regulations and manufacturing Parts 1 & 2

 

  • Developing scalable upstream workflows for recombinant and viral vaccine processes

 

  • Downstream process development for vaccine manufacturing

 

  • Implementing single-use technologies in formulation and filling of vaccines
Register